# Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS)

Source: https://onco.cc/trials/nct04313881/  
OnCo record `nct04313881` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Magrolimab and Azacitidine in Myelodysplastic syndromes / neoplasms, run by Gilead Sciences, recorded as terminated on the registry.

## Summary

Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS) is a phase 3 interventional study registered as NCT04313881 by Gilead Sciences, with 539 participants recorded, started 2020-09-09 and due to reach its primary completion in 2023-09-13. Interventions recorded: Magrolimab, Azacitidine, Placebo. Conditions recorded: Myelodysplastic Syndromes.

Linked to the drug Magrolimab because the registry names it among its interventions and Myelodysplastic syndromes / neoplasms among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04313881
- Phase: 3
- Setting: ENHANCE: A Randomized, Double-blind, Multicenter Study Comparing Magrolimab in Combination With Azacitidine Versus Azacitidine Plus Placebo in Treatment-naïve Patients With Higher Risk Myelodysplastic Syndrome
- Sponsor: Gilead Sciences
- Enrolled: 539

## Sources

- ClinicalTrials.gov NCT04313881: https://clinicaltrials.gov/study/NCT04313881

## Connected records

- cancers: [Myelodysplastic syndromes / neoplasms (MDS)](https://onco.cc/cancers/mds/)
- drugs: [Azacitidine](https://onco.cc/drugs/azacitidine/), [Magrolimab](https://onco.cc/drugs/magrolimab/)
- companies: [Gilead Sciences (incl. Kite)](https://onco.cc/companies/gilead/)

---
JSON: https://onco.cc/api/v1/entities/nct04313881.json